These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8214188)

  • 1. Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
    Lauterbach EC
    Am J Psychiatry; 1993 Nov; 150(11):1750. PubMed ID: 8214188
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 3. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent advances in the treatment of Parkinson's disease: the role of bromocriptine.
    Le Witt PA; Calne DB
    J Neural Transm; 1981; 51(1-2):175-84. PubMed ID: 7021769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease.
    Glantz RH; Bieliauskas L; Paleologos N
    Adv Neurol; 1987; 45():417-20. PubMed ID: 3825719
    [No Abstract]   [Full Text] [Related]  

  • 6. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
    Hely MA; Morris JG; Reid WG; O'Sullivan DJ; Williamson PM; Rail D; Broe GA; Margrie S
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):903-10. PubMed ID: 8057111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease, depression, and the on-off phenomenon.
    Friedenberg DL; Cummings JL
    Psychosomatics; 1989; 30(1):94-9. PubMed ID: 2913602
    [No Abstract]   [Full Text] [Related]  

  • 10. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
    Comella CL; Tanner CM; Ristanovic RK
    Ann Neurol; 1993 Nov; 34(5):710-4. PubMed ID: 8239565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Parkinson's disease in general practice.
    Wilson JA
    Scott Med J; 1986 Apr; 31(2):132-4. PubMed ID: 3738478
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of bromocriptine in the treatment of Parkinson's disease.
    Stern GM; Lees AJ; Shaw KM; Lander CM
    Adv Biochem Psychopharmacol; 1980; 23():267-70. PubMed ID: 7395617
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further experiences with low doses of bromocriptine in Parkinson's disease.
    Fahn S; Côté LJ; Barrett RE; Snider SR
    Adv Biochem Psychopharmacol; 1980; 23():255-60. PubMed ID: 7395615
    [No Abstract]   [Full Text] [Related]  

  • 17. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.